Last updated: February 7, 2025
Sponsor: Brooke Army Medical Center
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Massive Transfusion Group
Control Group
Clinical Study ID
NCT06699901
23-2559
HT9425-23-1-1074
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Receives ampicillin/sulbactam, cefazolin, cefepime, ceftriaxone, clindamycin,ertapenem, levofloxacin, metronidazole or pipercillin/tazobactam at any dose
Hospitalized or anticipated hospital admission
Exclusion
Exclusion Criteria:
Received the same antibiotic within the past 5 half-lives of the drug (e.g. receivedthe same antibiotic during a recent interval)
<18 years of age
Known pregnancy
Known Prisoner
Study Design
Total Participants: 417
Treatment Group(s): 2
Primary Treatment: Massive Transfusion Group
Phase:
Study Start date:
September 30, 2024
Estimated Completion Date:
September 30, 2027
Study Description
Connect with a study center
University of Colorado Hospital
Aurora, Colorado 80045
United StatesActive - Recruiting
Brooke Army Medical Center
Fort Sam Houston, Texas 78234
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.